Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Brouwers, Barbara" or (type exact bookEditor and editor="Brouwers, Barbara")

Add to list
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, et al.

(2019) CLINICAL CANCER RESEARCH. 25(6). p.1766-1773
Add to list
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Bram De Laere, Prabhakar Rajan, Henrik Gronberg, Luc Dirix, Johan Lindberg, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, et al.

(2019) JAMA ONCOLOGY. 5(7). p.1060-1062
Add to list
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, et al.

(2018) PROSTATE. 78(6). p.435-445
Add to list
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, et al.

(2018) GENOME MEDICINE. 10.
Add to list
BRCA2 hypomorphic missense variants confer moderate risks of breast cancer

Hermela Shimelis, Romy LS Mesman, Catharina Von Nicolai, Asa Ehlen, Lucia Guidugli, Charlotte Martin, Fabienne MGR Calléja, Huong Meeks, Emily Hallberg, Jamie Hinton, et al.

(2017) CANCER RESEARCH. 77(11). p.2789-2799

Academic Bibliography

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

BRCA2 hypomorphic missense variants confer moderate risks of breast cancer

Contents

Support

Contact